Year |
Citation |
Score |
2024 |
Barzi M, Chen T, Gonzalez TJ, Pankowicz FP, Oh SH, Streff HL, Rosales A, Ma Y, Collias S, Woodfield SE, Diehl AM, Vasudevan SA, Galvan TN, Goss J, Gersbach CA, ... ... Asokan A, et al. A humanized mouse model for adeno-associated viral gene therapy. Nature Communications. 15: 1955. PMID 38438373 DOI: 10.1038/s41467-024-46017-0 |
0.302 |
|
2024 |
Clements KN, Gonzalez TJ, Asokan A. Engineering Synthetic circRNAs for Efficient CNS Expression. Methods in Molecular Biology (Clifton, N.J.). 2765: 227-246. PMID 38381343 DOI: 10.1007/978-1-0716-3678-7_13 |
0.31 |
|
2023 |
Asokan A, Shen S. Redirecting AAV vectors to extrahepatic tissues. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37805712 DOI: 10.1016/j.ymthe.2023.10.005 |
0.584 |
|
2023 |
Gonzalez TJ, Mitchell-Dick A, Blondel LO, Fanous MM, Hull JA, Oh DK, Moller-Tank S, Castellanos Rivera RM, Piedrahita JA, Asokan A. Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery. Nature Protocols. PMID 37735235 DOI: 10.1038/s41596-023-00875-y |
0.328 |
|
2023 |
Smith TJ, Fusco RM, Elmore ZC, Asokan A. Interplay between Furin and Sialoglycans in Modulating Adeno-Associated Viral Cell Entry. Journal of Virology. e0009323. PMID 37097176 DOI: 10.1128/jvi.00093-23 |
0.385 |
|
2022 |
Yan R, Cigliola V, Oonk KA, Petrover Z, DeLuca S, Wolfson DW, Vekstein A, Mendiola MA, Devlin G, Bishawi M, Gemberling MP, Sinha T, Sargent MA, York AJ, Shakked A, ... ... Asokan A, et al. An enhancer-based gene-therapy strategy for spatiotemporal control of cargoes during tissue repair. Cell Stem Cell. PMID 36516837 DOI: 10.1016/j.stem.2022.11.012 |
0.303 |
|
2022 |
Gonzalez TJ, Simon KE, Blondel LO, Fanous MM, Roger AL, Maysonet MS, Devlin GW, Smith TJ, Oh DK, Havlik LP, Castellanos Rivera RM, Piedrahita JA, ElMallah MK, Gersbach CA, Asokan A. Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nature Communications. 13: 5947. PMID 36210364 DOI: 10.1038/s41467-022-33745-4 |
0.359 |
|
2021 |
Elmore ZC, Patrick Havlik L, Oh DK, Anderson L, Daaboul G, Devlin GW, Vincent HA, Asokan A. The membrane associated accessory protein is an adeno-associated viral egress factor. Nature Communications. 12: 6239. PMID 34716331 DOI: 10.1038/s41467-021-26485-4 |
0.32 |
|
2021 |
Havlik LP, Das A, Mietzsch M, Oh DK, Ark J, McKenna R, Agbandje-McKenna M, Asokan A. Receptor switching in newly evolved adeno-associated viruses. Journal of Virology. JVI0058721. PMID 34232726 DOI: 10.1128/JVI.00587-21 |
0.309 |
|
2021 |
Hunanyan AS, Kantor B, Puranam RS, Elliott C, McCall A, Dhindsa J, Pagadala P, Wallace K, Poe J, Gunduz T, Asokan A, Koeberl DD, ElMallah MK, Mikati MA. Adeno-Associated Virus-Mediated Gene Therapy in the Mashlool, , Mouse Model of Alternating Hemiplegia of Childhood. Human Gene Therapy. PMID 33577387 DOI: 10.1089/hum.2020.191 |
0.323 |
|
2020 |
Kwon JB, Ettyreddy AR, Vankara A, Bohning JD, Devlin G, Hauschka SD, Asokan A, Gersbach CA. Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy. Molecular Therapy. Methods & Clinical Development. 19: 320-329. PMID 33145368 DOI: 10.1016/j.omtm.2020.09.016 |
0.301 |
|
2020 |
Elmore ZC, Oh DK, Simon KE, Fanous MM, Asokan A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. Jci Insight. PMID 32941184 DOI: 10.1172/Jci.Insight.139881 |
0.41 |
|
2020 |
Madigan VJ, Berry GE, Tyson TO, Nardone-White D, Ark J, Elmore ZC, Murlidharan G, Vincent HA, Asokan A. The Golgi calcium ATPase pump plays an essential role in AAV trafficking and transduction. Journal of Virology. PMID 32817219 DOI: 10.1128/Jvi.01604-20 |
0.345 |
|
2020 |
Havlik LP, Simon KE, Smith JK, Klinc KA, Tse LV, Oh DK, Fanous MM, Meganck RM, Mietzsch M, Agbandje-McKenna M, Asokan A. Co-evolution of AAV capsid antigenicity and tropism through a structure-guided approach. Journal of Virology. PMID 32669336 DOI: 10.1128/Jvi.00976-20 |
0.434 |
|
2020 |
Li J, Li Y, Wang J, Gonzalez TJ, Asokan A, Napierala J, Napierala M. Defining transcription regulatory elements in the human frataxin gene: implications for gene therapy. Human Gene Therapy. PMID 32527155 DOI: 10.1089/Hum.2020.053 |
0.398 |
|
2020 |
Das A, Barrientos R, Shiota T, Madigan V, Misumi I, McKnight KL, Sun L, Li Z, Meganck RM, Li Y, Kaluzna E, Asokan A, Whitmire JK, Kapustina M, Zhang Q, et al. Gangliosides are essential endosomal receptors for quasi-enveloped and naked hepatitis A virus. Nature Microbiology. PMID 32451473 DOI: 10.1038/S41564-020-0727-8 |
0.401 |
|
2020 |
Huang Q, Cohen MA, Alsina FC, Devlin G, Garrett A, McKey J, Havlik P, Rakhilin N, Wang E, Xiang K, Mathews P, Wang L, Bock C, Ruthig V, Wang Y, ... ... Asokan A, et al. Intravital imaging of mouse embryos. Science (New York, N.Y.). 368: 181-186. PMID 32273467 DOI: 10.1126/Science.Aba0210 |
0.31 |
|
2019 |
Madigan VJ, Tyson TO, Yuziuk JA, Pillai M, Moller-Tank S, Asokan A. A CRISPR screen identifies the cell polarity determinant Crumbs 3 as an AAV restriction factor in hepatocytes. Journal of Virology. PMID 31391273 DOI: 10.1128/Jvi.00943-19 |
0.417 |
|
2019 |
Madigan VJ, Yuziuk JA, Chiarella AM, Tyson TO, Meganck RM, Elmore ZC, Tse LV, Hathaway NA, Asokan A. Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription. Plos Pathogens. 15: e1007988. PMID 31386698 DOI: 10.1371/Journal.Ppat.1007988 |
0.424 |
|
2019 |
Abdulhaqq SA, Wu H, Schell JB, Hammond KB, Reed JS, Legasse AW, Axthelm MK, Park BS, Asokan A, Früh K, Hansen SG, Picker LJ, Sacha JB. Vaccine-mediated Inhibition of the Transporter Associated with Antigen Processing is Insufficient to Induce MHC-E Restricted CD8+ T cells in Nonhuman Primates. Journal of Virology. PMID 31315990 DOI: 10.1128/Jvi.00592-19 |
0.3 |
|
2019 |
Albright BH, Simon KE, Pillai M, Devlin G, Asokan A. Modulation of sialic acid dependence influences the CNS transduction profile of adeno-associated viruses. Journal of Virology. PMID 30894463 DOI: 10.1128/Jvi.00332-19 |
0.452 |
|
2019 |
Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, Robinson-Hamm JN, Bulaklak K, Castellanos Rivera RM, Collier JH, Asokan A, Gersbach CA. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine. PMID 30778238 DOI: 10.1038/S41591-019-0344-3 |
0.345 |
|
2019 |
Castle MJ, Cheng Y, Asokan A, Tuszynski MH. IMPROVED INTRATHECAL VECTOR DELIVERY FOR GENE THERAPY IN ALZHEIMER’S DISEASE Alzheimer's & Dementia. 15: P1630. DOI: 10.1016/J.Jalz.2019.06.4868 |
0.367 |
|
2018 |
Castle MJ, Cheng Y, Asokan A, Tuszynski MH. Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion. Science Advances. 4: eaau9859. PMID 30443600 DOI: 10.1126/Sciadv.Aau9859 |
0.39 |
|
2018 |
Meganck RM, Borchardt EK, Castellanos Rivera RM, Scalabrino ML, Wilusz JE, Marzluff WF, Asokan A. Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo. Molecular Therapy. Nucleic Acids. 13: 89-98. PMID 30245471 DOI: 10.1016/J.Omtn.2018.08.008 |
0.384 |
|
2018 |
Tse LV, Moller-Tank S, Meganck RM, Asokan A. Mapping and Engineering Functional Domains of the Assembly Activating Protein of Adeno-Associated Viruses. Journal of Virology. PMID 29695425 DOI: 10.1128/Jvi.00393-18 |
0.342 |
|
2018 |
Crowther AJ, Lim SA, Asrican B, Albright BH, Wooten J, Yeh CY, Bao H, Cerri DH, Hu J, Ian Shih YY, Asokan A, Song J. An Adeno-Associated Virus-Based Toolkit for Preferential Targeting and Manipulating Quiescent Neural Stem Cells in the Adult Hippocampus. Stem Cell Reports. PMID 29478897 DOI: 10.1016/J.Stemcr.2018.01.018 |
0.373 |
|
2017 |
Burwitz BJ, Wettengel JM, Mück-Häusl MA, Ringelhan M, Ko C, Festag MM, Hammond KB, Northrup M, Bimber BN, Jacob T, Reed JS, Norris R, Park B, Moller-Tank S, Esser K, ... ... Asokan A, et al. Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. Nature Communications. 8: 2146. PMID 29247188 DOI: 10.1038/S41467-017-01953-Y |
0.342 |
|
2017 |
Albright BH, Storey CM, Murlidharan G, Castellanos Rivera RM, Berry GE, Madigan VJ, Asokan A. Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29175157 DOI: 10.1016/J.Ymthe.2017.10.017 |
0.422 |
|
2017 |
Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje-McKenna M, Asokan A. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proceedings of the National Academy of Sciences of the United States of America. PMID 28559317 DOI: 10.1073/Pnas.1704766114 |
0.407 |
|
2017 |
Zeng C, Moller-Tank S, Asokan A, Dragnea BG. Probing the Link between Genomic Cargo, Contact Mechanics and Nanoindentation in Recombinant Adeno-Associated Virus 2. The Journal of Physical Chemistry. B. PMID 28142241 DOI: 10.1021/Acs.Jpcb.6B10131 |
0.397 |
|
2016 |
Murlidharan G, Sakamoto K, Rao L, Corriher T, Wang D, Gao G, Sullivan P, Asokan A. CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Molecular Therapy. Nucleic Acids. 5: e338. PMID 28131242 DOI: 10.1038/mtna.2016.49 |
0.335 |
|
2016 |
Murlidharan G, Crowther A, Reardon RA, Song J, Asokan A. Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain. Jci Insight. 1: e88034. PMID 27699236 DOI: 10.1172/Jci.Insight.88034 |
0.423 |
|
2016 |
Berry GE, Asokan A. Cellular transduction mechanisms of adeno-associated viral vectors. Current Opinion in Virology. 21: 54-60. PMID 27544821 DOI: 10.1016/J.Coviro.2016.08.001 |
0.468 |
|
2016 |
Murlidharan G, Sakamoto K, Rao L, Corriher T, Wang D, Gao G, Sullivan P, Asokan A. CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Molecular Therapy. Nucleic Acids. 5: e338. PMID 27434683 DOI: 10.1038/Mtna.2016.49 |
0.438 |
|
2016 |
Tseng YS, Vliet KV, Rao L, McKenna R, Byrne BJ, Asokan A, Agbandje-McKenna M. Generation and characterization of anti-AAV8 and anti-AAV9 monoclonal antibodies. Journal of Virological Methods. PMID 27424005 DOI: 10.1016/J.Jviromet.2016.07.009 |
0.379 |
|
2016 |
Pierson EE, Keifer DZ, Asokan A, Jarrold MF. Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. Analytical Chemistry. PMID 27310298 DOI: 10.1021/Acs.Analchem.6B00883 |
0.343 |
|
2016 |
Madigan VJ, Asokan A. Engineering AAV receptor footprints for gene therapy. Current Opinion in Virology. 18: 89-96. PMID 27262111 DOI: 10.1016/J.Coviro.2016.05.001 |
0.417 |
|
2016 |
de Leeuw CN, Korecki AJ, Berry GE, Hickmott JW, Lam SL, Lengyell TC, Bonaguro RJ, Borretta LJ, Chopra V, Chou AY, D'Souza CA, Kaspieva O, Laprise S, McInerny SC, Portales-Casamar E, ... ... Asokan A, et al. rAAV-compatible MiniPromoters for restricted expression in the brain and eye. Molecular Brain. 9: 52. PMID 27164903 DOI: 10.1186/S13041-016-0232-4 |
0.405 |
|
2016 |
Huang LY, Patel A, Ng R, Miller EB, Halder S, McKenna R, Asokan A, Agbandje-McKenna M. Characterization of the Adeno-associated virus 1 and 6 sialic acid binding site. Journal of Virology. PMID 26962225 DOI: 10.1128/Jvi.00161-16 |
0.425 |
|
2016 |
Vance M, Llanga T, Bennett W, Woodard K, Murlidharan G, Chungfat N, Asokan A, Gilger B, Kurtzberg J, Samulski RJ, Hirsch ML. AAV Gene Therapy for MPS1-associated Corneal Blindness. Scientific Reports. 6: 22131. PMID 26899286 DOI: 10.1038/Srep22131 |
0.411 |
|
2016 |
Huang L, Patel A, Ng R, Miller EB, Halder S, McKenna R, Asokan A, Agbandje-McKenna M. 727. Characterizing the Adeno-Associated Virus 1 Sialic Receptor Binding Site and Its Overlap with Antigenic Epitopes Molecular Therapy. 24: S287. DOI: 10.1016/S1525-0016(16)33535-3 |
0.414 |
|
2016 |
Robinson-Hamm JN, Nelson CE, Rivera RMC, Aartsma-Rus A, Asokan A, Gersbach CA. 504. Restoration of Dystrophin Expression by Gene Editing with S. aureus Cas9 in Models of Duchenne Muscular Dystrophy Molecular Therapy. 24: S201. DOI: 10.1016/S1525-0016(16)33313-5 |
0.43 |
|
2016 |
Nelson C, Gemberling M, Hakim CH, Ousterout DG, Thakore PI, Castellanos RM, Madhavan S, Pan X, Ran FA, Yan W, Asokan A, Zhang F, Duan D, Gersbach CA. 482. Local and Systemic Gene Editing in a Mouse Model of Duchenne Muscular Dystrophy Molecular Therapy. 24: S191. DOI: 10.1016/S1525-0016(16)33291-9 |
0.385 |
|
2016 |
Murlidharan G, Asokan A. 55. Aquaporins and CSF Flux Are Critical Determinants of AAV Mediated CNS Gene Transfer Molecular Therapy. 24: S25. DOI: 10.1016/S1525-0016(16)32864-7 |
0.396 |
|
2016 |
Berry G, Murlidharan G, Asokan A. 30. Modulation of Intracellular Calcium Enhances AAV Transduction in the CNS Molecular Therapy. 24: S14. DOI: 10.1016/S1525-0016(16)32839-8 |
0.323 |
|
2016 |
Schreiber CA, Izumiya Y, Asokan A, Ikeda Y. 8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction Molecular Therapy. 24: S4-S5. DOI: 10.1016/S1525-0016(16)32817-9 |
0.455 |
|
2015 |
Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (New York, N.Y.). PMID 26721684 DOI: 10.1126/Science.Aad5143 |
0.403 |
|
2015 |
Berry GE, Asokan A. Chemical Modulation of Endocytic Sorting Augments Adeno-Associated Viral Transduction. The Journal of Biological Chemistry. PMID 26527686 DOI: 10.1074/Jbc.M115.687657 |
0.397 |
|
2015 |
Schreiber CA, Sakuma T, Izumiya Y, Holditch SJ, Hickey RD, Bressin RK, Basu U, Koide K, Asokan A, Ikeda Y. An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses. Plos Pathogens. 11: e1005082. PMID 26244496 DOI: 10.1371/Journal.Ppat.1005082 |
0.441 |
|
2015 |
Li C, Wu S, Albright B, Hirsch M, Li W, Tseng YS, Agbandje-McKenna M, McPhee S, Asokan A, Samulski RJ. Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26220272 DOI: 10.1038/Mt.2015.134 |
0.415 |
|
2015 |
Tse LV, Moller-Tank S, Asokan A. Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opinion On Biological Therapy. 15: 845-55. PMID 25985812 DOI: 10.1517/14712598.2015.1035645 |
0.422 |
|
2015 |
Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A. Optical Control of CRISPR/Cas9 Gene Editing. Journal of the American Chemical Society. 137: 5642-5. PMID 25905628 DOI: 10.1021/Ja512664V |
0.343 |
|
2015 |
Murlidharan G, Corriher T, Ghashghaei HT, Asokan A. Unique glycan signatures regulate adeno-associated virus tropism in the developing brain. Journal of Virology. 89: 3976-87. PMID 25631075 DOI: 10.1128/Jvi.02951-14 |
0.418 |
|
2015 |
Shen S, Berry GE, Castellanos Rivera RM, Cheung RY, Troupes AN, Brown SM, Kafri T, Asokan A. Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. The Journal of Biological Chemistry. 290: 1496-504. PMID 25404742 DOI: 10.1074/Jbc.M114.608281 |
0.618 |
|
2015 |
Nelson CE, Moreb DGOJNREA, Castellanos RM, Ran FA, Yan W, Zhang F, Asokan A, Gersbach CA. 397. Correction of the Dystrophin Gene By the CRISPR/Cas9 System in a Mouse Model of Muscular Dystrophy Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34006-0 |
0.435 |
|
2015 |
Albright BH, Madigan V, Rao L, Chiorini JA, Agbandje-McKenna M, Asokan A. 302. Combinatorial Engineering of a Receptor Footprint on AAV Serotype 4 Yields Novel Vectors Molecular Therapy. 23: S122. DOI: 10.1016/S1525-0016(16)33911-9 |
0.427 |
|
2015 |
Murlidharan G, Asokan A. 265. Polysialic Acid as a Novel Regulator of AAV Tropism in the Developing Brain Molecular Therapy. 23: S106. DOI: 10.1016/S1525-0016(16)33874-6 |
0.399 |
|
2015 |
Castellanos Rivera RM, Rao L, Murlidharan G, Corriher T, Asokan A. 194. Lymphatic Transport Mediates Systemic Leakage of Peripherally Administered AAV9 Vectors Molecular Therapy. 23: S77. DOI: 10.1016/S1525-0016(16)33799-6 |
0.428 |
|
2015 |
Rao L, Albright BH, Corriher T, Murlidharan G, Asokan A. 42. Differential Transduction Profiles of AAV Vectors in a Mouse Model of Human Glycosylation Molecular Therapy. 23: S18-S19. DOI: 10.1016/S1525-0016(16)33647-4 |
0.452 |
|
2015 |
Schreiber C, Sakuma T, Izumiya Y, Holditch S, Hickey R, Bressin R, Basu U, Koide K, Asokan A, Ikeda Y. 41. U2 snRNP Spliceosome Proteins Block Recombinant AAV Vector Transduction Molecular Therapy. 23: S18. DOI: 10.1016/S1525-0016(16)33646-2 |
0.465 |
|
2015 |
Berry GE, Asokan A. 38. Pharmacological Regulation of Vesicular Trafficking as a Strategy to Enhance Recombinant AAV Transduction Molecular Therapy. 23: S17. DOI: 10.1016/S1525-0016(16)33643-7 |
0.453 |
|
2015 |
Murlidharan G, Rao L, Wang D, Corriher T, Seok-Oh K, Gao G, Jude Samulski R, Tarantal AF, Asokan A. 14. Next Generation AAV Vectors for Limiting Systemic Leakage and Improving Safety Following CNS Administration Molecular Therapy. 23: S6. DOI: 10.1016/S1525-0016(16)33618-8 |
0.465 |
|
2014 |
Murlidharan G, Samulski RJ, Asokan A. Biology of adeno-associated viral vectors in the central nervous system. Frontiers in Molecular Neuroscience. 7: 76. PMID 25285067 DOI: 10.3389/Fnmol.2014.00076 |
0.429 |
|
2014 |
Pleticha J, Heilmann LF, Evans CH, Asokan A, Samulski RJ, Beutler AS. Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Molecular Pain. 10: 54. PMID 25183392 DOI: 10.1186/1744-8069-10-54 |
0.357 |
|
2014 |
Ishikawa K, Fish KM, Tilemann L, Rapti K, Aguero J, Santos-Gallego CG, Lee A, Karakikes I, Xie C, Akar FG, Shimada YJ, Gwathmey JK, Asokan A, McPhee S, Samulski J, et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2038-45. PMID 25023328 DOI: 10.1038/Mt.2014.127 |
0.317 |
|
2014 |
O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Asokan A, Boye SE, Crystal RG, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, et al. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy. 25: 488-97. PMID 24773122 DOI: 10.1089/Hum.2014.045 |
0.324 |
|
2013 |
Asokan A, Samulski RJ. An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Human Gene Therapy. 24: 906-13. PMID 24164238 DOI: 10.1089/Hum.2013.2515 |
0.423 |
|
2013 |
Shen S, Troupes AN, Pulicherla N, Asokan A. Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. Journal of Virology. 87: 13206-13. PMID 24067974 DOI: 10.1128/Jvi.02109-13 |
0.62 |
|
2013 |
Shen S, Horowitz ED, Troupes AN, Brown SM, Pulicherla N, Samulski RJ, Agbandje-McKenna M, Asokan A. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. The Journal of Biological Chemistry. 288: 28814-23. PMID 23940044 DOI: 10.1074/Jbc.M113.482380 |
0.603 |
|
2013 |
Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Falvo MR, Griffith JD, Harvey SC, Asokan A. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. Journal of Virology. 87: 2994-3002. PMID 23269804 DOI: 10.1128/Jvi.03017-12 |
0.33 |
|
2012 |
Asokan A, Schaffer DV, Jude Samulski R. The AAV Vector Toolkit: Poised at the Clinical Crossroads. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 699-708. PMID 28160612 DOI: 10.1038/mt.2011.287 |
0.33 |
|
2012 |
Shen S, Bryant KD, Sun J, Brown SM, Troupes A, Pulicherla N, Asokan A. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. Journal of Virology. 86: 10408-17. PMID 22787229 DOI: 10.1128/Jvi.01155-12 |
0.615 |
|
2012 |
Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A, Rabinowitz J, Agbandje-McKenna M, Samulski RJ. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. Journal of Virology. 86: 7752-9. PMID 22593151 DOI: 10.1128/Jvi.00675-12 |
0.429 |
|
2012 |
Denard J, Beley C, Kotin R, Lai-Kuen R, Blot S, Leh H, Asokan A, Samulski RJ, Moullier P, Voit T, Garcia L, Svinartchouk F. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. Journal of Virology. 86: 6620-31. PMID 22496229 DOI: 10.1128/Jvi.00297-12 |
0.41 |
|
2012 |
Horowitz ED, Finn MG, Asokan A. Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection. Acs Chemical Biology. 7: 1059-66. PMID 22458529 DOI: 10.1021/Cb3000265 |
0.374 |
|
2012 |
Pulicherla N, Kota P, Dokholyan NV, Asokan A. Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids. Plos One. 7: e32163. PMID 22389684 DOI: 10.1371/Journal.Pone.0032163 |
0.345 |
|
2012 |
Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 699-708. PMID 22273577 DOI: 10.1038/Mt.2011.287 |
0.434 |
|
2012 |
Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Therapy. 19: 288-94. PMID 21697954 DOI: 10.1038/Gt.2011.90 |
0.427 |
|
2011 |
Gray SJ, Choi VW, Asokan A, Haberman RA, McCown TJ, Samulski RJ. Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.17. PMID 21971848 DOI: 10.1002/0471142301.Ns0417S57 |
0.471 |
|
2011 |
Kapoor A, Hornig M, Asokan A, Williams B, Henriquez JA, Lipkin WI. Bocavirus episome in infected human tissue contains non-identical termini. Plos One. 6: e21362. PMID 21738642 DOI: 10.1371/Journal.Pone.0021362 |
0.337 |
|
2011 |
Pulicherla N, Asokan A. Peptide affinity reagents for AAV capsid recognition and purification. Gene Therapy. 18: 1020-4. PMID 21490687 DOI: 10.1038/Gt.2011.46 |
0.316 |
|
2011 |
Horowitz ED, Weinberg MS, Asokan A. Glycated AAV vectors: chemical redirection of viral tissue tropism. Bioconjugate Chemistry. 22: 529-32. PMID 21388193 DOI: 10.1021/Bc100477G |
0.452 |
|
2011 |
Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M, Asokan A. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1070-8. PMID 21364538 DOI: 10.1038/Mt.2011.22 |
0.618 |
|
2011 |
Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. The Journal of Biological Chemistry. 286: 13532-40. PMID 21330365 DOI: 10.1074/Jbc.M110.210922 |
0.614 |
|
2011 |
Phillips JL, Hegge J, Wolff JA, Samulski RJ, Asokan A. Systemic gene transfer to skeletal muscle using reengineered AAV vectors. Methods in Molecular Biology (Clifton, N.J.). 709: 141-51. PMID 21194026 DOI: 10.1007/978-1-61737-982-6_9 |
0.405 |
|
2010 |
Asokan A. Reengineered AAV vectors: old dog, new tricks. Discovery Medicine. 9: 399-403. PMID 20515607 |
0.326 |
|
2010 |
Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nature Biotechnology. 28: 79-82. PMID 20037580 DOI: 10.1038/Nbt.1599 |
0.467 |
|
2009 |
Li C, Goudy K, Hirsch M, Asokan A, Fan Y, Alexander J, Sun J, Monahan P, Seiber D, Sidney J, Sette A, Tisch R, Frelinger J, Samulski RJ. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proceedings of the National Academy of Sciences of the United States of America. 106: 10770-4. PMID 19541644 DOI: 10.1073/Pnas.0902269106 |
0.365 |
|
2009 |
Li C, Hirsch M, DiPrimio N, Asokan A, Goudy K, Tisch R, Samulski RJ. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. Journal of Virology. 83: 6817-24. PMID 19369348 DOI: 10.1128/Jvi.00278-09 |
0.427 |
|
2009 |
Li C, Hirsch M, Carter P, Asokan A, Zhou X, Wu Z, Samulski RJ. A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Therapy. 16: 43-51. PMID 18701910 DOI: 10.1038/Gt.2008.134 |
0.409 |
|
2008 |
Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Eugene Redmond D, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-1260. PMID 28178482 DOI: 10.1038/Mt.2008.100 |
0.476 |
|
2008 |
Asokan A, Johnson JS, Li C, Samulski RJ. Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Therapy. 15: 1618-22. PMID 18668144 DOI: 10.1038/Gt.2008.127 |
0.437 |
|
2008 |
Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Redmond DE, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-60. PMID 18500254 DOI: 10.1038/mt.2008.100 |
0.38 |
|
2008 |
DiPrimio N, Asokan A, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Surface loop dynamics in adeno-associated virus capsid assembly. Journal of Virology. 82: 5178-89. PMID 18367523 DOI: 10.1128/Jvi.02721-07 |
0.385 |
|
2007 |
Choi VW, Asokan A, Haberman RA, Samulski RJ. Production of recombinant adeno-associated viral vectors. Current Protocols in Human Genetics / Editorial Board, Jonathan L. Haines ... [Et Al.]. Unit 12.9. PMID 18428408 DOI: 10.1002/0471142905.Hg1209S53 |
0.464 |
|
2007 |
Choi VW, Asokan A, Haberman RA, Samulski RJ. Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Current Protocols in Molecular Biology / Edited by Frederick M. Ausubel ... [Et Al.]. Unit 16.25. PMID 18265393 DOI: 10.1002/0471142727.Mb1625S78 |
0.474 |
|
2007 |
Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, Kafri T, Samulski RJ. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. Journal of Virology. 81: 7540-7. PMID 17475652 DOI: 10.1128/Jvi.00529-07 |
0.463 |
|
2006 |
Choi VW, Asokan A, Haberman RA, McCown TJ, Samulski RJ. Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.17. PMID 18428636 DOI: 10.1002/0471142301.ns0417s35 |
0.378 |
|
2006 |
Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. Journal of Virology. 80: 11393-7. PMID 16943302 DOI: 10.1128/Jvi.01288-06 |
0.463 |
|
2006 |
Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. Journal of Virology. 80: 8961-9. PMID 16940508 DOI: 10.1128/Jvi.00843-06 |
0.413 |
|
2006 |
Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 316-27. PMID 16824801 DOI: 10.1016/J.Ymthe.2006.05.009 |
0.488 |
|
2006 |
Asokan A, Samulski RJ. AAV does the shuffle. Nature Biotechnology. 24: 158-60. PMID 16465157 DOI: 10.1038/Nbt0206-158 |
0.408 |
|
2006 |
Asokan A, Johnson JS, Samulski RJ. 739. Bioluminescent Virion Shells: A Novel Tool for Visualization of Viral Vectors in Animal Tissue Molecular Therapy. 13: S286. DOI: 10.1016/J.Ymthe.2006.08.821 |
0.461 |
|
2006 |
DiPrimio N, Asokan A, Samulski RJ. 104. Role of the HI Loop in the Adeno- Associated Virus (AAV) Life Cycle Molecular Therapy. 13: S43. DOI: 10.1016/J.Ymthe.2006.08.124 |
0.402 |
|
2006 |
Asokan A, Hamra JB, Agbandje-McKenna M, Samulski RJ. 7. Adeno-Associated Virus Type 2 (AAV2) Contains an Integrin alpha5beta1 Recognition Sequence Essential for Viral Cell Entry Molecular Therapy. 13: S3. DOI: 10.1016/J.Ymthe.2006.08.017 |
0.415 |
|
2005 |
Asokan A, Samulski RJ. From crystal structure to clinic: highlights of the Tenth International Parvovirus Workshop. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 656-60. PMID 15892211 DOI: 10.1016/J.Ymthe.2005.03.014 |
0.378 |
|
2003 |
Chen FJ, Asokan A, Cho MJ. Cytosolic delivery of macromolecules: I. Synthesis and characterization of pH-sensitive acyloxyalkylimidazoles. Biochimica Et Biophysica Acta. 1611: 140-50. PMID 12659955 DOI: 10.1016/S0005-2736(03)00049-X |
0.303 |
|
Show low-probability matches. |